This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2024 Mar 1;160(3):370.

doi: 10.1001/jamadermatol.2023.6198.

Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis

Andrew Blauvelt¹

Affiliations

PMID: 38353963
DOI: 10.1001/jamadermatol.2023.6198

Published Erratum

Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis

Andrew Blauvelt. JAMA Dermatol. 2024.

. 2024 Mar 1;160(3):370.

doi: 10.1001/jamadermatol.2023.6198.

Author

Andrew Blauvelt¹

Affiliation

¹ Oregon Medical Research Center, Portland.

PMID: 38353963
DOI: 10.1001/jamadermatol.2023.6198

No abstract available

PubMed Disclaimer

Erratum for

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K. Blauvelt A, et al. JAMA Dermatol. 2021 Sep 1;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023. JAMA Dermatol. 2021. PMID: 34347860 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems